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Description
Genomic DNA of MAL gene is located on chromosome 2q11.1 spans 21 kb and includes 4 exons interrupted by three introns. The promoter lacks a consensus TATA box in the vicinity of transcription start side and there is no consensus polyadenylation signal, although ATAAAA sequence exists.
There are two separated promoter CpG islands at a totally 1500 bp length of region extending into the first intron and contains up to 116 CpG dinucleotides. CpG island is divided into two regions and usually methylation status of these regions are evaluated separately by specifically designed primer sets. MAL promoter at 110 bp upstream of the transcriptional start site contains also several SP1 binding sites, which may be regulated by transcriptional activator SP1 (Tugores et al., 1997) .
Transcription
MAL coding sequence: bases 60-518, accession NM_002371.2. The mRNA is 1051 bp and open reading frame is 460 bp in length. Translation begins from a start codon in exon 1, ends at a stop codon in exon 4, and results in a 153 amino acid protein product. mRNA orientation is forward and transcription occurs on plus strand. The first exon encodes the 5' untranslated region and the first 31 amino acids. The second and the third exons encode 56 and 42 amino acids, respectively. Fourth exon encodes the 24 amino acids at COOH-terminal and the 3' untranslated region. The intron boundaries follow the AG/GT rule of acceptor/donor splice signal sequences and splicing between exons occurs between the last nucleotide of a codon and the first one of the next codon (Rancano et al., 1994b) .
Pseudogene
There is no identified pseudogene.
Protein
Description MAL belongs to the MAL family of proteolipids including BENE, MAL2 and Plasmolipin. In mouse, the conserved motif of (Q/Y-G-W-V-M-F/Y-V), which is located at the junction of the first extracellular loop and the second membrane-associated domain serves as a fingerprint for the MAL family, although overall amino acid sequence identities between mouse MAL and the related proteins are between 29-37% (Magyar et al., 1997) . This motif is also shared in human MAL family. Molecular mass of the MAL protein is 16700 Da and assigned into proteolipid group based on the solubility feature in lipophilic solvents. MAL is a nonglycosylated integral membrane protein including four transmembrane domains as hydrophobic segments. Each of four exons encodes a hydrophobic membraneassociated segment and its adjacent hydrophilic sequence in the protein structure (Rancano et al., 1994a) . A model is proposed about orientation of MAL protein in the membrane (Alonso et al., 1987) . Another feature of MAL is its transmembrane helices constituting the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain. This domain is also found approximately in 20 open reading frames of human genome (Sanchez-Pulido et al., 2002) . Furthermore, the domain is also found in the tight-junction-associated proteins including occluding, tricellulin, marvelD3 and in the synaptic-membranelocalized synaptophysin and synaptogyrin. Thus, a common characteristic of proteins containing the MARVEL domain is localization to specialized domains within surface membranes (Magal et al., 2009) .
Expression
Alonso and Weissman originally identified MAL expression in intermediate and late stages of Tlymphocyte differentiation (Alonso and Weissman, 1987) . Furthermore, expression of MAL mRNA is also found to be related with differentiation in urothelial cells, neuronal cells (Liebert et al., 1997; Wakeman et al., 1997) and esophageal epithelium (Mimori et al., 2007) . Accordingly, expression is prominent in upper layers, while it is weak or absent in basal layers of esophageal epithelium (Marazuela et al., 2003) . These results implied a strong relation between differentiation status and MAL expression. Although four transcripts identified, MAL-a variant containing the all four exons is found to be the most abundantly expressed in several tissues including peripheral blood lymphocytes and HNSCC tissues (Rancano et al., 1994b; Beder et al., 2009) . Maruzela et al. defined a detailed expression status for MAL protein by immunostaining in a wide range of human tissues and expression is found to be mainly localized in epithelial cells, myelinating cells and Tlymphocytes (Marazuela et al., 2003) . Detailed results according to this study: A-MAL negative cells and tissues: -Fibroblasts, endothelial cells, B lymphocytes, skeletal and smooth muscle, skin (keratinized squamous epithelium and subcutaneous fibro-adipose tissue). B-MAL positive cells and tissues: -Gastrointestinal tract: Epithelium in esophagus, stomach, ileum, colon, liver, and pancreas. -Genitourinary tract: Multiple sites of tract including transitional epithelium of the urothelium. -Respiratory tract: Ciliated columnar epithelium of bronchi and bronchioles, and type 2 pneumocytes of alveolae. -Hematopoietic system: Expression is restricted to regions rich in T-cells including cortex of thymus and paracortical lymphocytes of lymph node and tonsil. -Endocrine system: Thyroid follicular cells, medulla of adrenal gland. -Nervous system: Axons of peripheral nerves and myelinating Schwann cells in peripheral nervous system, oligodendrocytes of white and gray matter in central nervous system. -Exocrine glands: breast epithelium (Horne et al., 2009 ).
Localisation
The MAL proteolipid is an integral membrane protein and generally embedded in the plasma membrane of epithelial cells (Magal et al., 2009) . Expression is generally more pronounced in supranuclear -apical membrane domain for most of the polarized epithelia including gastrointestinal mucosa and thyroid follicular cells (Marazuela et al., 2003) according with its role in polarized sorting. The protein has been mainly identified as an internal component of glycolipid-enriched membrane (GEM) domains in T-lymphocytes (Millan et al., 1997) , in polarized epithelial MDCK cells (Zacchetti et al., 1995) and in myelin-forming cells (Kim et al., 1995) . As intracellular placement, the protein is localized to endoplasmic reticulum of T-lymphocytes (Rancano et al., 1994b) .
Function
Plasma membrane (PM) of epithelial cells divided into apical membrane domain involved in exchange with the organ lumen, and the basolateral domain maintaining contact with neighboring cells and the underlying extracellular matrix. Localizing numerous PM proteins to apical and basolateral domains by direct or indirect pathways result in cell polarization. In the direct pathway, proteins delivered directly from the trans-golgi network (TGN) to the apical PM by raftdependent or non-raft carriers. Rafts are clustering of glycospingolipids, sphingomyelin and cholesterol into membrane microdomains and therefore also named as GEM (glycosphingolipid-and cholestrol-enriched membrane) domains. These detergent insoluble membranes defined by resistancy to cold extraction with Triton X-100. Several proteins participate in structure of rafts. MAL is an integral membrane component of raft domains and recycles between the Golgi complex and the apical membrane in MDCK cells (Puertollano et al., 1999a) . Although, exact mechanism of MAL function in raft-dependent apical sorting is unknown, MAL family proteolipids are implicated to be potent regulator of apical transport by involving in the assembly and targeting of apical transport platforms and in the formation and stabilization of raft domains. Consensus sorting motifs in the C-terminus function in regulation of raft transport . In apical sorting, PM proteins are clustered into either glycolipid raft domains or non-raft carriers. MAL and MAL2 together with FAPP2 take part in constitutive apical transport of Influenza hemagglutinin (HA) (Puertollano et al., 1999b) and GPI-anchored proteins (decay-accelerating F factor, folate receptor, GFP-GPI, 5'-nucleotidase, CEA) by lipid-raft-associated mechanism (Weisz et al., 2009) . Based on apical sorting of many proteins, MAL is implied to function in establishment of cell polarity, however, MAL knockout mice did not display a clear defect in neuronal and epithelial cell polarity (Harada, 2010) . Related with the location of MAL in membrane microdomains another role is also suggested in cell signaling (Alonso et al., 2001 ), although there is yet no clear evidence concerning this function.
Homology
MAL protein is shown to be widely conserved (94-97%) across species by sequence alignment. In MAL family of human, MAL displays 39% and 36% amino acid sequence identity with BENE and MAL2, respectively and all proteins have four-transmembrane domain structure.
Mutations
Note Direct sequencing of the entire coding region revealed no somatic mutations in 20 cases of cervical cancers (Hatta et al., 2004) and in 24 head and neck cancer cell line series (Beder et al., 2009) . Currently, there is no further data in HGMD database.
Implicated in
Various cancers
Diagnostic biomarker in cancer: Recent reports revealed that epigenetic silencing of MAL by hypermethylation may be a common event involved during initiation and progression of epithelial cancers. Based on specifically high hypermethylation of MAL promoter in various carcinomas including breast, cervix, colon and gastric cancers compared to normal epithelium, promoter methylation of the gene is suggested to be diagnostic marker for early detection of tumorigenesis (Buffart et al., 2008; Lind et al., 2008; Horne et al., 2009; Overmeer et al., 2009) . Tumor-metastasis suppressive vs oncogenic role: Current functions attributed to MAL gene does not reveal a clear mechanism for MAL in oncogenesis. The gene is suggested to have tumor suppressive role in some malignancies, while oncogenic role in others according with expression level in tumors and normal tissues. In cervical carcinoma cell lines, MAL overexpression by transfection reduces proliferation rate and suppressed migration and anchorage-dependent growth. Furthermore, Fas-induced apoptosis is found to be related with reduced migration and tumorigenicity by ectopic expression of MAL in esophageal carcinoma (Mimori et al., 2003) .
Ovarian cancer
Note MAL mRNA is found to be the most differentially expressed gene between short and long-term survival groups by microarray study, and higher expression showed correlation with short survival (Berchuck et al., 2005) .
Esophageal carcinoma
Note MAL expression is severely down-regulated in esophageal carcinomas compared to normal epithelium (Mimori et al., 2003) and up-regulation of MAL expression induces differentiation in esophageal carcinoma cells (Mimori et al., 2007) .
Cervical carcinoma
Note MAL mRNA is found to be the most significantly down-regulated gene both in squamous cell carcinoma (SCC) and adenocarcinoma of cervix (Wilting et al., 2008) . Ectopic expression of MAL in SiHa cells suppressed proliferation, migration, and anchorageindependent growth. Promoter methylation is also remarkably high in cervical malignancies and accordingly showed significant correlation with decreased expression. Interestingly, promoter methylation is also shown to be predictive for highgrade lesions of cervix i.e. severity of cervical disease (Overmeer et al., 2009 ).
Colon carcinoma
Note Genome wide microarray analysis revealed MAL to be frequently hypermethylated in colon carcinoma cell lines correlating with down-regulation of mRNA expression (Mori et al., 2006) . Another study confirmed these results in carcinoma tissues and defined promoter hypermethylation as 71% (45/63) and 80% (49/61) in colon adenomas and carcinomas, respectively, while it is rare in normal mucosa. Furthermore, protein expression were also absent in majority (198/231) colorectal carcinoma tissues in immunostaining (Lind et al., 2008) . Based on these results, MAL methylation is suggested as a diagnostic marker for early colon carcinogenesis.
Gastric cancer
Note
Promoter hypermethylation located at the transcription start region is correlated with down-regulation of mRNA expression. Furthermore, methylation of this region is also significant related with a better survival (Buffart et al., 2008) .
Breast carcinoma
Note Tumor specific hypermethylation of the MAL promoter is found in 100% (6/6) of the breast cancer cell lines and 69% (25/36) of primary tumors. Ectopic expression of MAL in breast carcinoma cell lines reduced motility, while no effect was observed on cell cycle or growth. Absence of MAL protein expression was highly associated with poor disease-free survival in patients not received adjuvant chemotherapy (Horne et al., 2009 ).
Head and neck squamous cell carcinoma (HNSCC)
Note
In a review of DNA microarray analysis related with genetic expression profiles of HNSCC, MAL is found to be down-regulated in 10 out of the 26 studies (Choi et al., 2005) . Interestingly, MAL expression is downregulated in metastatic tumors of HNSCC including both cell lines derived from lymph node metastasis (65%) and metastatic tumor tissues (43%) compared to primary tumor counterparts. Furthermore, remarkable LOH (loss of heterozygosity) frequency (30%) is observed in primary tumor samples and metastatic tumors itself (Beder et al., 2009 ). These results suggest that loss of MAL expression may lead to metastasis in HNSCC.
Lymphoma
Note Like ovarian cancers, MAL overexpression is identified to be indicator for poor prognosis and disease outcome in patients with T cell lymphoma and Hodgkin lymphoma (Tracey et al., 2002; Hsi et al., 2006) .
